Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Topics Aug 08 | 2018SENS: Roche Acquisition Possible; Senseonics Q2 ’18 Earnings UpdatePurchase Blast
$599
Posted in: Glucagon, Topics Aug 08 | 2018Glucagon: New Xeris Market Survey Detailed in Investor PPTPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, Topics Aug 08 | 2018Novo Q2 ’18 Earnings UpdatePurchase Blast
$599
Posted in: Glucose Monitoring, Other, Topics Aug 07 | 2018ESI 2019 Formulary Exclusions; No Diabetes Drug ChangesPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Aug 07 | 2018Senseonics Launches Eversense Implantable CGMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other, Topics Aug 07 | 2018New Novo Ph1 Oral Peptide?Purchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Topics Aug 03 | 2018MannKind Q2 ’18 Earnings UpdatePurchase Blast
$599
Posted in: SGLT2i, Topics Aug 02 | 2018Invokana Receives Positive CHMP Opinion for CV IndicationPurchase Blast
$599
Posted in: Insulin Delivery, Topics Aug 02 | 2018BD Patch Pump Update; CY Q2 ’18 Earnings (FY Q3 ’18)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Topics Aug 01 | 2018Lilly’s New Diabetes Helpline to Aid Insulin AccessPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Topics Jul 31 | 2018Sanofi Q2 ’18 Earnings Update; Pfizer Discontinues Ph1 T1DM CompoundPurchase Blast
$599
Posted in: GLP-1RA, Topics Jul 30 | 2018New Ozempic Concentrations; Potential Autoinjector in Ph1 StudyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, SGLT2i, Topics Jul 27 | 2018Biocon/Mylan Glargine CRL; Biocon and Merck Q2 ’18 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Topics Jul 27 | 2018New Abbott Libre 14-Day Wear, 1-Hour Warm-up and Improved MARD ApprovedPurchase Blast